|

Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs

RECRUITINGSponsored by Queen Mary University of London
Actively Recruiting
SponsorQueen Mary University of London
Started2021-11-01
Est. completion2026-01-30
Eligibility
Age18 Years – 100 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04943588

Summary

We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.

Eligibility

Age: 18 Years – 100 YearsHealthy volunteers accepted
Inclusion Criteria:

* Adults over 18yrs old
* Willing to undergo hepatitis C testing
* Able and willing to give informed consent
* Willing to return in 12 months time for repeat testing
* Resident in area and not planning to leave the region

Exclusion Criteria:

* Unwilling to give consent
* Unwilling or unable to undergo the necessary procedures
* Clinically significant illness (other than HCV) or other major medical condition that may interfere with the subject's treatment, assessment or compliance with protocol.
* Co-morbidities limiting life expectancy to less than 12 months

Conditions2

Hepatitis C, ChronicLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.